Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.
J Pharmacol Exp Ther. 2010 Oct;335(1):42-50. doi: 10.1124/jpet.110.170159. Epub 2010 Jul 16.
Organic cation transporter 1 (OCT1; SLC22A1) seems to play a role in the efficacy and disposition of the widely used antidiabetic drug metformin. Genetic variants in OCT1 have been identified largely in European populations. Metformin is increasingly being used in Asian populations where the incidence of type 2 diabetes (T2D) is on the rise. The goal of this study is to identify genetic variants of OCT1 in Chinese and Japanese populations, which may potentially modulate response to metformin. We used recent data from the 1000 Genomes Project (Chinese and Japanese) and direct sequencing of selected amplicons of OCT1 in 66 DNA samples from Japanese patients with T2D. A total of six nonsynonymous variants were identified. Three of them (Q97K, P117L, and R206C) had not been functionally characterized previously and had allele frequencies of 0.017, 0.023 and 0.008, respectively. The uptake of metformin in cells expressing Q97K, P117L, and R206C was significantly reduced relative to the OCT1 reference (62 ± 4.3, 55 ± 6.8, and 22 ± 1.5% for Q97K, P117L, and R206C, respectively). Kinetic studies indicated that P117L and R206C exhibited a reduced V(max), whereas Q97K showed an increased K(m). The green fluorescent protein (GFP)-tagged Q97K and P117L variants localized to the plasma membrane, whereas the GFP-tagged R206C was retained mainly in the endoplasmic reticulum. Replacement of the highly conserved R206 with different amino acids modulated the subcellular localization and function of the transporter. This study suggests that nonsynonymous variants of OCT1 in Chinese and Japanese populations may affect the differential response to metformin.
有机阳离子转运体 1(OCT1;SLC22A1)似乎在广泛使用的抗糖尿病药物二甲双胍的疗效和分布中发挥作用。OCT1 的遗传变异主要在欧洲人群中被发现。二甲双胍在亚洲人群中的使用越来越多,亚洲人群中的 2 型糖尿病(T2D)发病率正在上升。本研究的目的是鉴定中国和日本人群中 OCT1 的遗传变异,这些变异可能会调节对二甲双胍的反应。我们使用了来自 1000 基因组计划(中国和日本)的最新数据,并对 66 例日本 T2D 患者的 OCT1 选定扩增子进行了直接测序。共鉴定出 6 个非同义变异。其中 3 个(Q97K、P117L 和 R206C)以前没有进行过功能表征,等位基因频率分别为 0.017、0.023 和 0.008。与 OCT1 参考相比,表达 Q97K、P117L 和 R206C 的细胞对二甲双胍的摄取显著降低(Q97K、P117L 和 R206C 分别为 62±4.3%、55±6.8%和 22±1.5%)。动力学研究表明,P117L 和 R206C 表现出 Vmax 降低,而 Q97K 表现出 K m 增加。绿色荧光蛋白(GFP)标记的 Q97K 和 P117L 变体定位于质膜,而 GFP 标记的 R206C 主要保留在内质网中。用不同的氨基酸替代高度保守的 R206 可调节转运体的亚细胞定位和功能。本研究表明,中国和日本人群中 OCT1 的非同义变异可能影响对二甲双胍的不同反应。